Latest project updates
Oncode Institute aims to outsmart cancer and impact lives. To achieve this, Oncode focuses on three pillars: excellent research, intensive collaboration and powerful valorization. The research strategy is focused on understanding the basic mechanisms of cancer to realize the ultimate goal: safer and more effective medical solutions as well as personalized precision diagnostics. Oncode brings together excellent cancer researchers in The Netherlands: 61 research groups from 12 different Dutch research institutes collaborate on 6 interdisciplinary research themes. To speed up the translation of scientific discoveries into clinical applications, Oncode has a dedicated team of specialists to support scientists in the valorization process.
12 partner institutions
61 Principal Investigators
€ 120 million
funding for 5 years
About Oncode Institute
Over the past decades, the scientific and medical community has made tremendous progress in understanding and treating cancer. However, the disease still has a large burden on society as cancer has become the primary cause of death in The Netherlands. In an effort to address this unmet clinical need, Dutch cancer researchers have joined forces within Oncode Institute. To come up with new avenues for treatment and diagnosis, Oncode focuses on better understanding the fundamental mechanisms of cancer biology. With the ultimate goal to improve long-term survival and the quality of life of patients.Oncode serves as a platform for excellent cancer researchers in The Netherlands to collaborate, share knowledge, expertise and technology. As a virtual Institute it stimulates scientific freedom and offers dedicated support to optimize the translation of fundamental insights into clinical applications. Outsmarting cancer, impacting lives. Visit the Oncode website for more information about the project.
Over 800+ Oncode researchers working under a single strategy that focuses on six different research themes:
- Development of novel technologies
- Understanding the critical drivers of tumour growth and the causes of resistance
- Analysis of network perturbations in tumours and tumour-host interactions
- Causes and consequences of genetic instability
- Identification of critical drug combinations and biomarkers for personalized cancer treatments
- Mobilising immune defence
Oncode invests heavily in the transfer of results from fundamental research into clinical applications. A team of dedicated specialists will help Oncode researchers with valorization of their findings. Furthermore, Oncode offers tailored training programs for affiliated researchers and actively invests in diversity through its Young Female Investigator program.
Accelerating innovation by partnership management
Based on its broad experience with partnership management and communication, Lygature has become a partner of Oncode. Lygature supports Oncode Institute with the following services:
- Program management
- Communication & external affairs
- Finance & IT-infrastructure
- Patient engagement
Lygature together with
Project updates
-
Official launch of Immagene: Dutch company developing next-generation immuno-oncology therapeutics
Immagene B.V. launched this month as a private biotech company developing next-generation precision immuno-oncology (IO) treatments. The company based in Amsterdam announced its launch following a successful fundraise from Oncode Bridge Fund, Swanbridge Capital, and Innovatiefonds Noord Holland. Immagene is a spin-off of the Netherlands Cancer Institute (NKI) and Oncode Institute.
-
The platform that allows researchers to fully exploit available CRC studies is now available
About a year ago Oncode Investigator Louis Vermeulen (Amsterdam UMC) and clinician Miriam Koopman (UMC Utrecht) met at Oncode’s first clinical workshop about colorectal cancer. They knew each other already, but at the workshop they decided to work together to improve prospects for colorectal cancer (CRC) patients.
The result of their collaboration is the CRC platform (part of the larger BBMRI platform) which connects researchers and clinicians by allowing the sharing of clinical samples to exploit available data to its full potential.
-
Beyond Distancing: Science and Community at the Oncode Annual Scientific Meeting
Our two-day Oncode Annual Scientific Meeting this month was our very first hybrid event. With a full program on both days, around 100 participants present in person each day at the Van Nelle Fabriek in Rotterdam, and more than 230 participants on average online per day, we now look back feeling both proud and relieved. Proud of an event that was successful, and relieved that this has shown that though we do need to respect the rules of social distancing, we don’t have to stay or feel apart.